Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit

Epilepsy and Behavior

Volumn 49, Issue , 2015, Pages 354-358

  Rohracher, A ^a,b   Hofler J ^a,b   Kalss, G ^a,b   Leitinger, M ^a,b   Kuchukhidze, G ^a,b   Deak, I ^a,b   Dobesberger, J ^a,b   Novak, H ^a,b   Pilz, G ^a,b   Zerbs, A ^a,b   Trinka, E ^a,b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Glutamate; Noncompetitive AMPA receptor antagonist; Perampanel; Refractory status epilepticus; Seizure

Indexed keywords

GLUTAMIC ACID; PERAMPANEL; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; ANTICONVULSIVE AGENT; PYRIDONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ADULT; AGED; ARTICLE; AUSTRALIA; BRAIN TUMOR; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DELTA RHYTHM; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; EPILEPTIC STATE; FEMALE; GLASGOW OUTCOME SCALE; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; NASOGASTRIC DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PERSISTENT VEGETATIVE STATE; REFRACTORY PERIOD; RETROSPECTIVE STUDY; THETA RHYTHM; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COMA; COMPLICATION; DRUG EFFECTS; DRUG RESISTANT EPILEPSY; ELECTROENCEPHALOGRAPHY; INTENSIVE CARE; LENGTH OF STAY; MIDDLE AGED; STATUS EPILEPTICUS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICONVULSANTS; COMA; CRITICAL CARE; DRUG RESISTANT EPILEPSY; ELECTROENCEPHALOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PYRIDONES; RECEPTORS, AMPA; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84938978728     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.04.005     Document Type: Article

References (25)

1. Neligan A., Shorvon S. Frequency and prognosis of convulsive status epilepticus of different causes. Arch Neurol 2010, 67:931-940.
2. Logroscino G., Hesdorffer D.C., Cascino G., Annegers J.F., Hauser W.A. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997, 38:1344-1349.
3. Logroscino G., Hesdorffer D.C., Cascino G., Hauser W.A., Coeytaux A., Galobardes B., et al. Mortality after a first episode of status epilepticus in the United States and Europe. Epilepsia 2005, 46(Suppl. 11):46-48.
4. http://www.ilae.org/visitors/publications/Epigraph-2014-1-winter.cfm.
5. Chen J.W., Wasterlain C.G. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006, 5(3):246-256.
6. Naylor D.E., Liu H., Wasterlain C.G. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005, 25(34):7724-7733.
7. DeLorenzo R.J., Towne A.R., Pellock J.M., Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia 1992, 33(Suppl. 4):15-25.
8. Trinka E. The clinical forms and the treatment of status epilepticus. Klin Neurophysiol 2012, 43:144-150.
9. Meierkord H., Boon P., Engelsen B., Gocke K., Shorvon S., Tinuper P., et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010, 17:348-355.
10. Deeb T.Z., Maguire J., Moss S.J. Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia 2012, 53(Suppl. 9):79-88.
11. Hanada T., Ido K., Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect 2014, 2(5):e00063. 10.1002/prp2.63.
12. Pitkanen A., Mathiesen C., Ronn L.C., Moller A., Nissinen J. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 2007, 74:45-54.
13. Fritsch B., Stott J.J., Joelle Donofrio J., Rogawski M.A. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52446. Epilepsia 2010, 51:108-117.
14. Rajasekaran K., Todorovic M., Kapur J. Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol 2012, 72:91-102.
15. Rösche J., Kampf C., Benecke R. Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurol Belg 2014, 114(3):243-244.
16. Kaplan P.W., Sutter R. Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia 2012, 53(Suppl. 3):1-51.
17. Beniczky S., Hirsch L.J., Kaplan P.W., Pressler R., Bauer G., Aurlien H., et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 2013, 54(Suppl. 6):28-29.
18. Beghi E., Carpio A., Forsgren L., Hesdorffer D.C., Malmgren K., Sander J.W., et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia 2010, 51(Suppl. 4):671-675.
19. Rossetti A.O., Logroscino G., Milligan T.A., Michaelides C., Ruffieux C., Bromfield E.B. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008, 255(10):1561-1566.
20. Leitinger M., Höller Y., Kalss G., Rohracher A., Novak H.F., Höfler J., et al. Epidemiology-Based Mortality Score in Status Epilepticus (EMSE). Neurocrit Care 2015, 22(2):273-282. 10.1007/s12028-014-0080-y.
21. Patsalos P.N. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia 2015, 56(1):12-27.
22. Caravias G. Perampanel in posthypoxic myoclonus. Poster presented at "The 4th London-Innsbruck Colloquium on status epilepticus and acute seizures" Salzburg, Austria, April 4th-6th 2013. Epilepsia 2014, 54 Supp. 6:113.
23. Caravias G., Geit M., Vosko M., Ransmayr G. Perampanel - effective and safe via percutaneous gastric tube in HIV epileptic patient with concomitant highly active antiretroviral therapy. Epilepsia 2014, Supp. 2:51.
24. Chapman M.J., Nguyen N.Q., Deane A.M. Gastrointestinal dysmotility: evidence and clinical management. Curr Opin Clin Nutr Metab Care 2013, 16(2):209-216.
25. Deane A.M., Rayner C.K., Keeshan A., Cvijanovic N., Marino Z., Nguyen N.Q., et al. The effects of critical illness on intestinal glucose sensing, transporters, and absorption. Crit Care Med 2014, 42(1):57-65.